- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00005342
Weight Set-Point and HDL Concentration in Runners
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
BACKGROUND:
The elevated high-density lipoprotein (HDL) cholesterol concentrations of long distance runners has been ascribed almost exclusively to increased muscle lipoprotein lipase. Based on data collected in cross-sectional and longitudinal studies, the investigators proposed an alternative theory: long-distance runners had the HDL-cholesterol metabolism of men who were below their sedentary weight rather than the HDL-cholesterol metabolism of lean sedentary men who were at their usual sedentary weight. In other analyses, they found that the most significant determinant of male runners' plasma HDL-cholesterol concentrations was the difference between the runners' greatest weight and their current weight. HDL- cholesterol levels were highest in runners who had lost the most weight, i.e., highest in those who were presumed to be the furthest below their weight set-point
The study was a result of a Program Announcement (PA) released in October, 1994 on Physical Activity and Cardiopulmonary Health. The PA was jointly sponsored by the NHLBI, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Nursing Research.
DESIGN NARRATIVE:
In this cross-sectional study, runners and sedentary men and women were measured for lipoprotein cholesterol, triglycerides, polyacrylamide gel electrophoresis of HDL and low-density lipoprotein subclasses, apolipoproteins A-I and B, intravenous fat clearance rate, post-heparin lipoprotein lipase and hepatic lipase, adipose tissue lipoprotein lipase, cholesteryl ester transfer activity, diet, percent body fat, and regional adiposity. It was hoped that the survey would confirm or reject the weight set-point hypothesis, provide a possible explanation of the lipoprotein differences between male and female runners, and elucidate the mechanism for the lipoprotein changes that occur during exercise-induced weight loss.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Studietype
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Studie plan
Hoe is de studie opgezet?
Medewerkers en onderzoekers
Publicaties en nuttige links
Algemene publicaties
- Williams PT, Krauss RM. Associations of age, adiposity, menopause, and alcohol intake with low-density lipoprotein subclasses. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1082-90. doi: 10.1161/01.atv.17.6.1082.
- Williams PT, Dreon DM, Blanche PJ, Krauss RM. Variability of plasma HDL subclass concentrations in men and women over time. Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):702-6. doi: 10.1161/01.atv.17.4.702.
- Williams PT. Deviations from maximum weight predict high-density lipoprotein cholesterol levels in runners: the National Runners' Health Study. Int J Obes Relat Metab Disord. 1997 Jan;21(1):6-13. doi: 10.1038/sj.ijo.0800352.
- Williams PT. Evidence for the incompatibility of age-neutral overweight and age-neutral physical activity standards from runners. Am J Clin Nutr. 1997 May;65(5):1391-6. doi: 10.1093/ajcn/65.5.1391.
- Williams PT. Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners. The National Runners' Health Study. Arch Intern Med. 1997 Jan 27;157(2):191-8.
- Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med. 1996 May 16;334(20):1298-303. doi: 10.1056/NEJM199605163342004.
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 4205
- R01HL045652 (Subsidie/contract van de Amerikaanse NIH)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hartziekten
-
University Hospital TuebingenVoltooidHeart Assist-apparaatDuitsland
-
Carmel Medical CenterOnbekendPneumoperitoneum | Heart Output StoornisIsraël
-
Region SkaneAanmelden op uitnodigingHartfalen New York Heart Association (NYHA) Klasse II | Hartfalen New York Heart Association (NYHA) Klasse IIIZweden
-
University of ChicagoVoltooidHartfalen | Heart Assist-apparaat | HyponatremischVerenigde Staten
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University... en andere medewerkersNog niet aan het wervenHartfalen, systolisch | Hartfalen met verminderde ejectiefractie | Hartfalen New York Heart Association Klasse IV | Hartfalen New York Heart Association Klasse IIIPolen
-
Triple-Gene, LLCIntrexon Corporation; Precigen, IncVoltooidHart-en vaatziekten | Hartfalen | Heart-Assist-apparaatVerenigde Staten
-
University of WashingtonAmerican Heart AssociationVoltooidHartfalen, congestief | Mitochondriale verandering | Hartfalen New York Heart Association Klasse IVVerenigde Staten
-
Novartis PharmaceuticalsVoltooidPatiënten die de behandelingsperiode van 12 maanden van de kernstudie met succes hebben afgerond (de Novo Heart-ontvangers) die geïnteresseerd waren om behandeld te worden met EC-MPS
-
University of PennsylvaniaVoltooidPatiënten met primaire of secundaire diagnose Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Behalve wanneer het 5e cijfer 2 was)Verenigde Staten
-
SpringWorks Therapeutics, Inc.VerkrijgbaarNeurofibromatose Type 1-geassocieerde plexiforme neurofibromen | Histiocytisch neoplasma | Andere MAP-K Pathway Driven Diseases